Non-Hodgkin Lymphoma by Clinical Course

Non-Hodgkin Lymphoma by Clinical Course — Trials · CancerIndex

Clinical trials

Registered studies

1,200 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 346
Recruiting: 173
Ph III recruiting: 8
Growth YoY: +32.7%
Industry share: 19%
Top sponsor: National Cancer Institute (NCI)
Termination share: 36.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (209)

clinicaltrialsPublishedShowing 51–100 of 127 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05665062	Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies	active not recruiting	Phase 1	36	SynthekineINDUSTRY	1	Jul 10, 2026	clinicaltrials
NCT07691450	Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma	not yet recruiting	Phase 1	40	City of Hope Medical CenterOTHER	1	Jul 9, 2026	clinicaltrials